Zoetis Inc. (ZTS)

Market Cap	65.74B
Revenue (ttm)	9.39B
Net Income (ttm)	2.61B
Shares Out	443.18M
EPS (ttm)	5.82
PE Ratio	25.48
Forward PE	22.66
Dividend	$2.00 (1.35%)
Ex-Dividend Date	Jul 18, 2025

Volume	1,159,191
Open	146.29
Previous Close	146.25
Day's Range	146.29 - 148.19
52-Week Range	139.70 - 200.33
Beta	0.89
Analysts	Buy
Price Target	200.25 (+35.0%)
Earnings Date	Nov 3, 2025

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 13,800
• Stock Exchange: NYSE
• Ticker Symbol: ZTS
• Website: https://www.zoetis.com

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Analyst Summary

According to 8 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $200.25, which is an increase of 35.00% from the latest price.

Price Target

$200.25

(35.00% upside)

Analyst Consensus: Buy